Dr. John Cush RheumNow
4 years 2 months ago
Study of 420 active #AS patients not responding to bDMARDs (TNFi, IL-17i) randomised to upadacitinib 15 mg/d or placebo. By wk14, UPA was superior by ASAS40 (45 vs 18%; p<0.0001)& other secondary endpoints (p<0.0001). https://t.co/nfOLlxgP5d https://t.co/fROMep8tbT
Dr. John Cush RheumNow
4 years 2 months ago
JAMA full read on wt loss and type 2 diabetes.
- Diet, physical activity, & behavioral therapy
- high frequency counseling (≥16 sessions/6 mos)
- Wt medications effective as adjuncts to diet etc
- Rec surgery if BMI >40, unable to lose # or comorbidity
https://t.co/lgbNVPr8tz https://t.co/bzmdOvnxC7
Dr. John Cush RheumNow
4 years 2 months ago
GLORIA trial presented by Martin Boxers. 2 yr RCT, 5mg Pred vs. PBO shows DAS28 benefit (-0.37 to -0.62) & -1.7 better X-ray (vs PBO) at 2yrs. BUT signif more harm (AE) RR 1.24; mostly infx. Is this a good trade off? Abst# OP0263 #EULAR2022 https://t.co/sjuOqDSjrM https://t.co/vniyDI77qE
Dr. John Cush RheumNow
4 years 2 months ago
#AOSD cause is unknown, but matched case control study suggests signif link to Stressful life events (OR 2.56) & nonsignificant risk trending towards coal dust exposure (OR 3.0), allergy prior to onset (OR 2.67) & oral contraceptive use (OR 2.0) https://t.co/Saa4gEbzKS https://t.co/87RKgojmGZ
Horizon has announced that the U.S. Food and Drug Administration (FDA) has approved the expanded labeling of pegloticase (Krystexxa) injection to be co-administered with methotrexate (MTX), to improve response rates in patients with uncontrolled gout.
Dr. John Cush RheumNow
4 years 2 months ago
Proposed investigations (findings) in the diagnosis of Stills disease:
- CRP, ESR, Ferritin (high)
- W/U for infection, cancer (negative)
- Serologies (negative)
- consider Imaging (CXR, CT, US, PET)
https://t.co/l3yqAx6PA0 https://t.co/Sg7okwKHaw
Dr. John Cush RheumNow
4 years 2 months ago
Guidelines for MAS complicating Systemic JIA: Dx is based on:
- Fever in sJIA with ^ ferritin > 684, plus
- Any 2 of these: elevated PLTs, AST, Triglycerides or low Fibrinogen
https://t.co/aIEvxRYZca https://t.co/DYpLHxRCzI
With the recent publication of the third iteration of the GRAPPA Psoriatic Arthritis (PsA) treatment recommendations, it seems to be an auspicious time to reflect on some key considerations that arose during the development of the recommendations, as well as to look towards what the future may hold.
Dr. John Cush RheumNow
4 years 2 months ago
Cyclic GMP–AMP synthase (cGAS) engages stimulator of interferon genes (STING) to trigger inflammatory cytokines & type I interferons. cGAS–STING activation by genomic or mitochondrial self DNA implicated in autoinflammatory & autoimmune dz https://t.co/7CEFt9wLrl https://t.co/HpHhjJOATd
Dr. John Cush RheumNow
4 years 2 months ago
Five Mistakes When Diagnosing Still’s Disease
AOSD is likely to be the adult continuum of systemic-onset juvenile arthritis (sJIA) and hence, frequently affects young men and women below the age of 35 years.
https://t.co/C9kUOpFIlc https://t.co/82GIA7hSJl
Dr. John Cush RheumNow
4 years 2 months ago
Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts.
Note 100% fatigue resolution roughly same vs. placebo
@RheumNow #EULAR2022 ABST#POS0305 cc: @doctorRBC : https://t.co/sodp75Nblw
Dr. John Cush RheumNow
4 years 2 months ago
Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/wWJhlY5IYW
cc: @RichardPAConway : https://t.co/2IAURdfAOB
Dr. John Cush RheumNow
4 years 2 months ago
#EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial cc: @Yuz6Yusof https://t.co/1tDBNzTuwQ
Dr. John Cush RheumNow
4 years 2 months ago
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA.
@RheumNow #EULAR2022 ABST#POS0331
cc: @doctorRBC https://t.co/M8YYAOBVat
